Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice

Peptides

Volumn 52, Issue , 2014, Pages 134-142

  Shao, Yimin ^a   Yuan, Geheng ^a   Feng, Yan ^b   Zhang, Junqing ^a   Guo, Xiaohui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Huguosi Hospital of Traditional Chinese Medicine   (China)

Author keywords

Cell; Early intervention; Liraglutide; T2DM

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; LIRAGLUTIDE; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR PDX 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; EARLY INTERVENTION; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HISTOPATHOLOGY; INSULIN RESPONSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; WEIGHT GAIN; WILD TYPE;

EARLY INTERVENTION; LIRAGLUTIDE; T2DM; Β-CELL;

ANIMALS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; EATING; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEODOMAIN PROTEINS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MAF TRANSCRIPTION FACTORS, LARGE; MALE; MICE; RECEPTORS, GLUCAGON; TRANS-ACTIVATORS;

EID: 84892732921     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.11.011     Document Type: Article

References (45)

1. A. Amato, L. Cinci, A. Rotondo, R. Serio, M.S. Faussone-Pellegrini, and M.G. Vannucchi et al. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors Neurogastroenterol Motil 22 2010 203 664
2. T. Bailey Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm Am J Med 126 2013 S10 S20
3. P.L. Brubaker, and D.J. Drucker Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors Receptors Channels 8 2002 179 188
4. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, and P.C. Butler Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110
5. A. Coppola, L. Tomasello, G. Pizzolanti, I. Pucci-Minafra, N. Albanese, and G. Di Cara et al. In vitro phenotypic, genomic and proteomic characterization of a cytokine-resistant murine beta-TC3 cell line PLoS One 7 2012 e32109
6. M.J. Dailey, and T.H. Moran Glucagon-like peptide 1 and appetite Trends Endocrinol Metab 24 2013 85 91
7. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 80 1995 952 957
8. C.F. Deacon, L. Pridal, L. Klarskov, M. Olesen, and J.J. Holst Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig Am J Physiol 271 1996 E458 E464
9. A. Edvell, and P. Lindstrom Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?) Endocrinology 140 1999 778 783
10. 2+ concentration J Biol Chem 273 1998 33501 33507
11. G.P. Fadini, N. Simioni, V. Frison, M. Dal Pos, M. Bettio, and P. Rocchini et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients Acta Diabetol 50 2013 943 949
12. A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, and I. Olvera-Alvarez et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
13. A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, and B. Bode Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 13 2011 348 356
14. T. Hansotia, B. Yusta, and D.J. Drucker Activation of GLP-1 receptor signaling is coupled to inhibition of apoptosis in heterologous cell types Diabetes 502 2001 A350
15. O. Heinisch Burington, R.S.: handbook of mathematical tables and formulas Biom Z 8 1966 281
16. P.M. Hellstrom, E. Naslund, T. Edholm, P.T. Schmidt, J. Kristensen, and E. Theodorsson et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome Neurogastroenterol Motil 20 2008 649 659
17. J.C. Henquin, and J. Rahier Pancreatic alpha cell mass in European subjects with type 2 diabetes Diabetologia 54 2011 1720 1725
18. N. Imeryuz, B.C. Yegen, A. Bozkurt, T. Coskun, M.L. Villanueva- Penacarrillo, and N.B. Ulusoy Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms Am J Physiol 273 1997 G920 G927
19. H. Kaneto, T. Miyatsuka, Y. Fujitani, H. Noguchi, K.H. Song, and K.H. Yoon et al. Role of PDX-1 and MafA as a potential therapeutic target for diabetes Diabetes Res Clin Pract 77 Suppl. 1 2007 S127 S137
20. M. Karaca, C. Magnan, and C. Kargar Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention Diabetes Metab 35 2009 77 84
21. K. Kou, Y. Saisho, S. Satoh, T. Yamada, and H. Itoh Change in beta-cell mass in Japanese nondiabetic obese individuals J Clin Endocrinol Metab 98 2013 3724 3730
22. V. Lyssenko, P. Almgren, D. Anevski, R. Perfekt, K. Lahti, and M. Nissen et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes Diabetes 54 2005 166 174
23. T.A. Matsuoka, H. Kaneto, T. Miyatsuka, T. Yamamoto, K. Yamamoto, and K. Kato et al. Regulation of MafA expression in pancreatic beta-cells in db/db mice with diabetes Diabetes 59 2010 1709 1720
24. D.R. Matthews, C.A. Cull, I.M. Stratton, R.R. Holman, and R.C. Turner UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group Diabet Med 15 1998 297 303
25. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 214 1993 829 835
26. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
27. M.A. Nauck, I. Weber, I. Bach, S. Richter, C. Orskov, and J.J. Holst et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients Diabet Med 15 1998 937 945
28. M.A. Nauck, D. Wollschlager, J. Werner, J.J. Holst, C. Orskov, and W. Creutzfeldt et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM Diabetologia 39 1996 1546 1553
29. C. Orskov, J.J. Holst, S. Knuhtsen, F.G. Baldissera, S.S. Poulsen, and O.V. Nielsen Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas Endocrinology 119 1986 1467 1475
30. R. Perfetti, J. Zhou, M.E. Doyle, and J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600 4605
31. U. Ribel, M.O. Larsen, B. Rolin, R.D. Carr, M. Wilken, and J. Sturis et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs Eur J Pharmacol 451 2002 217 225
32. R.C. Rogers, D.M. McTigue, and G.E. Hermann Vagal control of digestion: modulation by central neural and peripheral endocrine factors Neurosci Biobehav Rev 20 1996 57 66
33. B. Rolin, M.O. Larsen, C.F. Gotfredsen, C.F. Deacon, R.D. Carr, and M. Wilken et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am J Physiol Endocrinol Metab 283 2002 E745 E752
34. Y. Saisho, A.E. Butler, E. Manesso, D. Elashoff, R.A. Rizza, and P.C. Butler Beta-cell mass and turnover in humans: effects of obesity and aging Diabetes Care 36 2013 111 117
35. A.R. Saltiel, and C.R. Kahn Insulin signalling and the regulation of glucose and lipid metabolism Nature 414 2001 799 806
36. T. Schwasinger-Schmidt, D.C. Robbins, S.J. Williams, L. Novikova, and L. Stehno-Bittel Long-term liraglutide treatment is associated with increased insulin content and secretion in beta-cells, and a loss of alpha-cells in ZDF rats Pharmacol Res 76 2013 58 66
37. 2 results in insufficient insulin secretion and impaired glucose tolerance Mol Endocrinol 19 2005 504 515
38. C. Tan, U. Voss, S. Svensson, D. Erlinge, and B. Olde High glucose and free fatty acids induce beta cell apoptosis via autocrine effects of ADP acting on the P2Y(13) receptor Purinergic Signal 9 2013 67 79
39. J.F. Todd, J.P. Wilding, C.M. Edwards, F.A. Khan, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus Eur J Clin Invest 27 1997 533 536
40. B.L. Wajchenberg Beta-cell failure in diabetes and preservation by clinical treatment Endocr Rev 28 2007 187 218
41. G.J. Wang, D. Tomasi, W. Backus, R. Wang, F. Telang, and A. Geliebter et al. Gastric distention activates satiety circuitry in the human brain Neuroimage 39 2008 1824 1831
42. G. Xu, H. Kaneto, D.R. Laybutt, V.F. Duvivier-Kali, N. Trivedi, and K. Suzuma et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes Diabetes 56 2007 1551 1558
43. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
44. G.H. Yuan, W.L. Song, Y.Y. Huang, X.H. Guo, and Y. Gao Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study Chin Med J (Engl) 125 2012 2677 2681
45. Z. Zhao, C. Zhao, X.H. Zhang, F. Zheng, W. Cai, and H. Vlassara et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis Endocrinology 150 2009 2569 2576